Adynxx (OTCMKTS:ADYX) and IceCure Medical (NASDAQ:ICCM) Head-To-Head Contrast

Adynxx (OTCMKTS:ADYX) and IceCure Medical (NASDAQ:ICCM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Risk & Volatility

Adynxx has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Profitability

This table compares Adynxx and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adynxx	N/A	N/A	N/A
IceCure Medical	-410.22%	-111.27%	-81.41%

Earnings & Valuation

This table compares Adynxx and IceCure Medical’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adynxx	N/A	N/A	N/A	N/A	N/A
IceCure Medical	$3.34 million	8.75	-$14.65 million	($0.33)	-1.94

Adynxx has higher earnings, but lower revenue than IceCure Medical.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Adynxx and IceCure Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adynxx	0	0	0	0	N/A
IceCure Medical	0	0	2	0	3.00

IceCure Medical has a consensus price target of $2.70, indicating a potential upside of 321.88%.

Insider & Institutional Ownership

0.6% of IceCure Medical shares are owned by institutional investors. 17.4% of Adynxx shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Adynxx beats IceCure Medical on 5 of the 8 factors compared between the two stocks.

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.